Johnson & Johnson Acquires Ollin Biosciences for $2.2 Billion to Advance Phase 3 Retinal Drug in the US
Johnson & Johnson agrees to acquire Ollin Biosciences for $2.2 billion, adding Phase 3 retinal drug candidate OLN324 to its ophthalmology pipeline.
Research Desk
Johnson & Johnson announced that it has entered into a definitive agreement to acquire Ollin Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapies for serious eye diseases.
The deal is valued at USD 2.2 billion upfront, with the potential for additional regulatory and commercial milestone payments of up to approximately USD 1.125 billion. The transaction is expected to close before the end of 2026, subject to applicable regulatory approvals and customary closing conditions.
A Bispecific Antibody Aimed at Two Retinal Pathways
At the center of the transaction is OLN324, an investigational bispecific antibody currently in Phase 3 development for retinal vascular diseases, including wet age-related macular degeneration and diabetic macular edema.
According to Johnson & Johnson's announcement, those conditions affect well over 40 million people worldwide and are leading causes of vision loss. The molecule is designed to target two key pathways in retinal diseases: vascular endothelial growth factor, known as VEGF, and angiopoietin-2, known as Ang2.
Johnson & Johnson describes OLN324 as a next-generation antibody with high Ang2 potency and a small protein format, referred to as a minibody, that could enable improved control of retinal fluid.
Kip Connor, Vice President and Ophthalmology Disease Area Stronghold Leader at Johnson & Johnson, said the compound selectively targets two important drivers of retinal disease and has the potential to achieve stronger and more sustained disease control.
He stated that the data generated to date are compelling and point to a potentially transformative clinical profile that could deliver more effective reduction of retinal fluid and allow more time between treatments, ultimately redefining what is possible for patients.
Blackstone Steps In to Fund Phase 3 Development
Alongside the acquisition, Johnson & Johnson will enter into a separate development funding agreement with Blackstone Life Sciences to support the Phase 3 clinical advancement of OLN324, contingent upon the acquisition's close.
Under that arrangement, Blackstone will pay a total of USD 750 million to Johnson & Johnson over multiple years to fully fund the Phase 3 development of OLN324. In return, Blackstone will be eligible to receive certain regulatory and sales milestone payments as well as single-digit royalties.
The accounting treatment will be communicated on or before the close of the transaction.
Strategic Rationale for Johnson & Johnson
The acquisition would add OLN324 to Johnson & Johnson's pipeline. The company stated that its combination of scientific, development, and commercial capabilities positions it to advance OLN324 and build on Ollin's promising science.
Johnson & Johnson framed the proposed acquisition as strengthening its leadership in ophthalmology and its commitment to preserve, restore, and enhance vision for millions of people worldwide.
The deal is also described as accelerating the company's ambition to preserve, restore, and enhance vision and as building on Johnson & Johnson's long-standing presence as an innovator in vision.
Tracked in the database
Ophthalmology Drug Development and Acquisitions · North America
Ophthalmology Drug Development and Acquisitions
North America
Chemical
17 November 2026
2 min read
Tagged
Also read
Biocon Secures European Commission Approval for Pertuzumab Biosimilar Pebrilzo in HER2-Positive Breast Cancer
Nanoform Partners With European CDMO to Manufacture High-Concentration Biologics Under GMP in Germany
LOTTE Biologics Signs First Commercial Manufacturing Agreement for Songdo Plant 1 in South Korea
Live from the tracker
The projects behind these stories
Capacity, capex, stage, contractors and verified contacts for every project we track, updated daily.